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Giardia is a leading but treatable cause of infectious
gastroenteritis worldwide, with a reported prevalence of 2-7%
in high income countries and 2-30% in low income countries.1
Giardiasis is included in the World Health Organization
Neglected Diseases Initiative owing to its burden and association
with poverty.2 Its incidence in the United Kingdom is
underestimated because of the lack of diagnostic sensitivity of
traditional faecal microscopy3 and the mistaken belief that it is
mostly acquired abroad, so often only people reporting foreign
travel are tested. This update discusses the epidemiology, clinical
presentation, diagnosis, and management of giardiasis
specifically in high income countries.
What is Giardia?
Giardia lamblia (synonyms G duodenalis and G intestinalis)
is a flagellated protozoan. Giardia is transmitted through the
ingestion of the infective cyst stage shed in human or animal
faeces and might be present in faecally contaminated water,
food, or fomites. G lamblia comprises eight genetic
“assemblages” (named A to H), of which only A and B cause
disease in humans but which can also infect pets, livestock, and
wild animals and show potential for zoonotic
transmission.4Figure 1⇓ depicts the life cycle and transmission
of Giardia. The actively multiplying trophozoite form of the
organism hatches from the cyst and attaches to the small
intestine (fig 2a⇓),5 where it induces epithelial inflammation,
villous flattening, and diarrhoea due to malabsorption.6-8 In the
large intestine, the trophozoites differentiate forming new cysts
(fig 2b⇓), which are shed in the faeces and contaminate the
environment. Cysts present in faeces can remain viable in a
variety of environments, particularly water and at lower
temperatures: viability can range from 28 to 84 days in lake or
river water9 but is reduced in soil10 or cattle slurry.11
Who gets giardiasis?
Box 1 summarises the risk factors for acquisition of Giardia in
high income countries. Travel to low income settings is a
common risk factor, with the highest risk areas being South
Asia and South East Asia, North Africa, the Caribbean, and
South America.25 26Giardia is the most common intestinal
pathogen in travellers returning to countries such as the UK
with gastrointestinal disorders.25-27However, a case-control study
in north west England in 2013 found that 75% of cases were
acquired in the UK.12Between 3000 and 4000 cases are reported
annually in England and Wales.28 However, detection of cases
increased fourfold after the introduction of an enzyme linked
immunosorbent assay for the detection of parasite antigens in
stools,3 and another study estimated there were 50 000
community cases of giardiasis between April 2008 and August
2009.29The highest incidence of giardiasis is in under 5s and
adults aged 25-44 years3-30: most studies report giardiasis being
more common in males,3-21 and it is more often reported in late
summer and early autumn in temperate regions such as the UK
and United States.13 30
The source of many infections is unknown but is likely to be
person-to-person transmission through exposure to human
faeces, including sexual transmission.22 In a recent prevalence
survey in northwest England, 30% of households in which a
family member had a diagnosis ofGiardia had a second person
with a stool sample positive forGiardia.31Outbreaks have been
reported in daycare centres and custodial
institutions,20 32favoured by overcrowding and poor hygienic
conditions.
When to consider Giardia?
Giardia infections can be asymptomatic (estimated in 5-15%
of infected people),33 but typical symptoms include diarrhoea,
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What you need to know
• The number of patients detected with Giardia will increase as routine testing of stool samples using highly sensitive diagnostic tests
becomes more widespread
• Most patients with Giardia in the UK acquire their infection in the UK and not from overseas travel
• Tinidazole and metronidazole are equally effective as first line treatments, although tinidazole has a simpler regimen and fewer side
effects
• Second line agents used in cases of treatment failure are unlicensed for giardiasis in the UK but are routinely used in many countries
• Asymptomatic carriage of Giardia is common among household contacts, and testing of contacts is indicated in treatment failure and
in household clusters
Sources and selection criteria
We searched PubMed and Medline from 1980 to 2016 for authoritative reviews and research articles on Giardia and giardiasis, which were
added to clinical experience, national guidelines, and personal reference collections. We also searched the Cochrane database and reference
lists in review articles. Searching was limited to publications in English.
Box 1: Risk factors for Giardia acquisition in high income countries
• Foreign travel, particularly in low income settings12-16
• Toileting young children and changing nappies12-15
• Drinking contaminated water or swallowing contaminated water while using swimming pools or other recreational fresh waters12-19
• Attending childcare settings20
• Eating fresh products raw18 21
• Sexual transmission22
• Dog ownership (Giardia assemblage A)12
• Some immunodeficiency disorders: X linked agammaglobulinaemia, common variable immunodeficiency23 24
flatulence, abdominal pain, and bloating.33 In the early stage of
disease, diarrhoea is often explosive, especially in the morning,
and the stool is difficult to flush away. Blood in the stool is
unusual34 and would suggest the presence of another pathogen.
Patients sometimes mention “eggy burps” of uncertain cause.
Later, the diarrhoea becomes more intermittent, with periods
of normal bowel function interspersed with the diarrhoea.
Weight loss due to malabsorption occurs in more than 80% of
patients, with a typical loss of 5 kg in adults over four or more
weeks35; chronic infection in children might result in failure to
thrive.36 Intestinal lactase deficiency occurs in up to 40% of
patients with giardiasis and might persist for several weeks after
parasite eradication.8 This manifests as diarrhoea that is worse
after consumption of food or drugs containing lactose. Rarer
symptoms include vomiting and fever.33 Patients often present
with diarrhoea but without typical symptoms of giardiasis and
the condition is diagnosed unexpectedly by microbiological
examination of a stool specimen. Examination is usually
unremarkable apart from features of weight loss, but patients
with prolonged symptomsmight have features of malabsorption,
including pallor due to anaemia. Diagnosis is often delayed,
sometimes for months, owing to the insidious onset and
relapsing clinical course.
Giardia and irritable bowel syndrome
The symptoms of giardiasis can resemble irritable bowel
syndrome (IBS).37 An Italian study of 137 patients investigated
in secondary care for IBS or dyspepsia found Giardia in 6.5%
of patients.38However, this finding was not replicated in a larger
study39 and guidance from the UK National Institute for Health
and Care Excellence recommends that faecal testing for ova
and parasites is not routinely required to confirm the diagnosis
of IBS in people who meet the diagnostic criteria for IBS.40 41
Clinicians should be alert to the possibility of both diagnoses.
If there is any doubt, or where there is a relevant exposure
history for giardiasis (box 1) consider parasitological
examination of a stool sample.
How should suspected giardiasis be
investigated?
Giardiasis is usually diagnosed by laboratory analysis of stool
samples (table 1⇓), either by traditional microscopy (ova, cysts,
and parasites (OCP) examination) for visualisation of cysts (or
more rarely, trophozoites) or by stool antigen detection assays.3-43
The sensitivity of antigen detection assays is superior to
microscopy for the diagnosis of giardiasis, but sensitivity
between different formats varies (table 1⇓). Highly sensitive
molecular methods (polymerase chain reaction, PCR) that
contain parasitology panels are increasingly being used but are
not universally available in UK laboratories.44 45 Not all
laboratories routinely test stool samples for the microorganism,
so specifically request examination of samples for Giardia and
document travel or other risk factor history. Owing to variable
shedding, three stool specimens (ideally taken two or three days
apart) might need to be examined when traditional microscopy
is used. If the result is negative, three more specimens should
be submitted at weekly intervals,51 with a minimum of six
negative results required for microscopic exclusion of infection.52
There is evidence of improved detection of Giardia in single
stool samples using PCR over microscopy of several stool
samples or antigen detection assays.46 47 At present PCR is only
offered as a first line test in a few UK hospital laboratories, and
clinicians are advised to discover what tests are available in
their local laboratory. In secondary care when giardiasis is highly
suspected but stool results are negative, diagnosis can be made
through duodenal aspiration and biopsy, which have been shown
to detect infection in the absence of cysts on stool
microscopy.39 48 Serological tests for circulating IgG and IgM
antibodies toGiardia are not appropriate for clinical diagnosis.
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2016;355:i5369 doi: 10.1136/bmj.i5369 (Published 27 October 2016) Page 2 of 9
PRACTICE
What treatments are available for
giardiasis?
Unlike many causes of infectious gastroenteritis, giardiasis is
treatable (table 2⇓). Many drugs have been evaluated in reviews
and several meta-analyses,53-59 including a Cochrane Review in
2012 that examined 19 trials for the effectiveness of the four
agents most commonly used to treat giardiasis—metronidazole,
tinidazole, albendazole, and nitazoxanide.54 Trials included in
these reviews are of variable quality and heterogeneous in their
location and types and ages of patients included. Some trials
have been conducted in low income settings where there is a
high prevalence of Giardia infections, and where the resulting
partial immunity might alter the clinical picture and observed
response to treatment compared with that observed in
non-endemic countries or in non-immune people. In most
analyses, the 5 nitroimidazoles metronidazole and tinidazole
have similar efficacies, with parasitological cure rates and
symptom relief in more than 90% of patients.
Symptomatic patients
The British National Formulary60 currently recommends a five
day course of metronidazole as preferred treatment in the UK.
Most specialists prescribe a single dose of tinidazole, which is
licensed for this indication, has similar efficacy to a multiple
dose metronidazole regimen, and is better tolerated.57 Repeat
either course if unsuccessful, together with exclusion of
reinfection (from a household or sexual contact) or lactose
intolerance. Advise patients to avoid milk and milk products
for at least two weeks (some clinicians advise up to six weeks)
to evaluate whether persisting symptoms truly represent
treatment failure rather than temporary lactose intolerance.
Giardiasis is associated with prolonged symptoms that can have
a detrimental impact on quality of life.61 62 Second line agents
such as albendazole or nitazoxanide are routinely available in
some countries but are not licensed for the treatment of giardiasis
in the UK. Specialist advice is recommended if second line
agents are required. Albendazole has similar efficacy to
metronidazole and is better tolerated.55 59 Nitazoxanide is more
difficult to obtain and more expensive in the UK, and
paromomycin is the only second line agent that can be used in
pregnancy.Mepacrine (quinacrine) is effective but has numerous
side effects and is reserved for management of refractory cases
by specialists.
Confirmation of treatment failure is best provided by PCR,
which offers improved detection in single stool samples over
microscopy.63 64 Treatment success is indicated by complete
resolution of symptoms or lack of detection of Giardia DNA
by PCR one week after treatment.
Treatment failure might be due to host factors or to true drug
resistance, which is well recognised and increasingly common,
particularly in travellers returning from South Asia and South
East Asia.16-65However, tinidazole or metronidazole should still
be used as first line treatment for travellers returning from these
areas despite cross resistance between these drugs.65 Patients
with treatment failure should be discussed with or referred to a
specialist, who should exclude underlying problems such as
coeliac disease, inherited disaccharidase deficiency, and
immunodeficiency disorders, particularly of total and IgA
antibody production.23-61Combination treatment with the above
agents may be used under specialist care.
A variety of combination treatments are effective, although the
evidence is based on observational studies and individual
clinician preference.56-69 Combinations of albendazole and a 5
nitroimidazole, or nitazoxanide with a second agent, are the
usual next steps in the treatment ladder. Paromomycin and
mepacrine have specific niches, as already discussed.
Asymptomatic patients
Asymptomatic carriage of Giardia is common in contacts of
cases, and household clusters do occur. In a recent study in north
west England, routine testing of all household contacts of 91
primary Giardia cases found a contact positive for Giardia in
27 households (30%): of the 212 contacts, 41 (19%) were
positive, most of whomwere asymptomatic.31 In the absence of
research as to whether treatment of asymptomatic carriage is
effective in curtailing transmission, management is based on
expert opinion.53Asymptomatic carriage is generally not treated,
but treatment is rational in failed treatment of a case or in
household clusters. In these situations a pragmatic alternative
may be to offer blind treatment to all household contacts based
on their preference. Wider availability of sensitive PCR
diagnostic tests may allow a more targeted approach to contact
treatment in future.
Can Giardia infection be prevented?
Individual cases require investigation, usually by environmental
health officers, to prevent onward spread and identify likely
exposures. In many high income countries, including the UK,
surveillance is underpinned by statutory notification ofGiardia
diagnoses by hospital laboratories to the local public health
system.70-72 Prevention of secondary transmission is mainly
through antiparasitic treatment of cases and advice on the
prevention of person-to-person spread through stringent personal
hygiene (box 2). Exclusion on the basis of the absence of
diarrhoea for 48 hours applies to children in nurseries, food
handlers, and those caring for vulnerable adults.73
Microbiological evidence of stool clearance is not usually
required, but this might be considered in outbreak situations.
Giardia cysts are more resistant to chlorine disinfection than
most bacteria, and outbreaks have been reported linked to
contaminated mains drinking water, swimming pools, and
paddling pools.17 19Adherence to guidelines for swimming pool
management74 reduces the risk of giardiasis to a minimum.
Outbreaks due to drinking water are uncommon in the UK75
because of the full treatment of public water supplies (filtration
and disinfection), but they are a risk where treatment is
inadequate. Travellers should check that water disinfection
filters or systems they use are certified to remove Giardia.
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Box 2: Advice on Giardia for patients and carers
General
• Wash your hands carefully with soap and hot water and dry them thoroughly each time you go to the toilet or before preparing food
• Do not share towels
• Remain off work until free of diarrhoea for 48 hours if you work with food or in social care or healthcare and have direct contact with
patients or clients
Young children with Giardia
• Ensure scrupulous hygiene when changing nappies
• Supervise children’s hand washing
• Keep young children away from playgroups, childminders, or nursery until free of diarrhoea for 48 hours
Household contacts of a Giardia case
Testing is not advised unless the original patient remains unwell despite treatment or if someone else becomes unwell
How patients were involved in the creation of the article
No patients were involved in the creation of this review.
Questions for ongoing and future research
• What behavioural or immunological factors could explain the excess of giardiasis in males?
• What is the extent of zoonotic transmission risk for Giardia?
• Do different Giardia lamblia genetic assemblages differ in transmission and clinical outcome of disease?
• Is previous exposure to Giardia protective against successive infections in travellers?
• What is the relation between Giardia and irritable bowel syndrome or other post-infectious gastrointestinal disorders?
• Why are some infections refractory to treatment?
• How common is drug resistance and what is the molecular basis of resistance?
• What is the most effective and safe treatment for refractory infections?
• Is treatment of asymptomatic excretors effective in curtailing transmission, and, if so, when should it be offered?
• Is there a role for prebiotics or probiotics in prevention or management of infection?
Education into practice
Do you request specific Giardia testing in patients presenting with relapsing diarrhoea, negative results on bacterial stool culture, and no
history of overseas travel?
Additional educational resources
Information for healthcare professionals
• Public Health England (www.gov.uk/guidance/giardia)—for surveillance information and epidemiological trends of giardiasis
• USCenters for Disease Control and Prevention (www.cdc.gov/parasites/giardia/audience-health-professionals.html)—for epidemiological
information and links to veterinary and environmental aspects of Giardia
Information for patients
• US Centers for Disease Control and Prevention (www.cdc.gov/parasites/giardia/)—provides answers to frequently asked questions
about Giardia
• New Zealand Ministry of Health (www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-illnesses/food-and-water-
borne-diseases/giardia)—has general information about giardiasis
• Patient website (http://patient.info/health/giardia)—has an information leaflet with preventive advice
• National Travel Health Network and Centre (NaTHNaC) (http://travelhealthpro.org.uk/travellers-diarrhoea/)—provides pre-travel advice,
as well as links to country specific advice
• Fit for Travel (www.fitfortravel.nhs.uk/advice/disease-prevention-advice/travellers-diarrhoea.aspx)—provides similar pre-travel advice
on hygiene and disease prevention
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Tables
Table 1| Comparison of diagnostic tests for Giardia42434445464748495051
CommentsRelative diagnostic performance for
Giardia
Usual test (target)Specimen type by patient
group
Specificity (%)Sensitivity (%)
Any patient with community acquired or unexplained diarrhoea
May not detect low level, chronic infection. Provides
differential diagnosis of many (but not all) parasites.
Smaller parasites will be missed (eg, Cryptosporidium;
microsporidia). Labour intensive; high level of skill
required; cheap. Most useful where burden of illness
and intensity of infection is high
100*31*Ova, cysts, and parasites (OCP)
examination by microscopy of
unconcentrated and concentrated
preparations from which
permanent stained smears can be
made (cysts; trophozoites may be
Most preserved or
unpreserved stool
seen, although some preservatives
may affect their morphology)
Only provides diagnosis of specific parasites included
in assay; often in combination with Cryptosporidium
and sometimes Entamoeba histolytica. Useful for high
throughput testing; kit cost maybe offset by use of low
skilled staff
≥9585-100Enzyme immunoassay (cyst
antigens)
Formalin or SAF preserved†
or unpreserved stool
Only provides diagnosis of specific parasites included
in assay. Useful where there is low capacity for complex
testing; expensive
97.1-10095.8-100Immunochromatographic lateral
flow (cyst antigens)
Formalin or SAF preserved†
or unpreserved stool
Only provides diagnosis of specific parasites included
in assay. Useful where other highly sensitive and
specific tests are not available, for confirmation of
equivocal results, and where the burden and intensity
of infection is low. Labour intensive; moderate level of
skill required; fluorescent microscope needed;
expensive.
10094-100Immunofluorescent microscopy
(cysts)
Formalin or SAF preserved†
or unpreserved stool
Only provides diagnosis of specific parasites included
in assay. Useful for high throughput testing. Kit cost
maybe offset by decreased staff time. Improves
diagnosis where burden of illness and intensity of
infection is low. Rapidly becomes negative after
successful treatment. Sensitivity and specificity can
75-10090-100Nucleic acid amplification based
(PCR)
Unpreserved stool or only
those in specified
preservatives†
vary according to sample processing, amplification
approach, and molecular marker chosen
Patients where Giardia is suspected but not detected in stool
Will probably be supplanted in most cases by sensitive PCR stool assays, but occasionally useful
in areas where this and antigen assays are not available
Microscopy (trophozoites) or
nucleic acid amplification based
(DNA), flattening of villi (histology)
Duodenal or jejunal biopsy
or aspirate collected through
intubation or string test
(Entero-test)
SAF=sodium acetate-acetic acid formalin solution.
*Using PCR as reference test.50
†Other preservatives may interfere with assay performance. Refer to kit insert.
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Table 2| Current treatment options for Giardia in UK*
Licensed in UKUse in childrenUse in pregnancyDrug
YesYesAvoid first trimester if possibleMetronidazole
YesYesAvoid first trimester if possibleTinidazole
NoYesNoAlbendazole
NoYesNoNitazoxanide
NoYesYesParomomycin
NoNoNoMepacrine (quinacrine)
*Many are unlicensed in the UK (see text for indications for these in secondary care practice).
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Figures
Fig 1 Life cycle and transmission of Giardia
Fig 2 (a) Trophozoites under electron microscopy. (b) Giardia cysts on microscopy
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